ICMR - NICED


ICMR-National Institute of Cholera and Enteric Diseases

आई सी एम आर - राष्ट्रीय कॉलरा और आंत्र रोग संस्थान

Department of Health Research, Ministry of Health and Family Welfare, Government of India
स्वास्थ्य अनुसंधान विभाग, स्वास्थ्य और परिवार कल्याण मंत्रालय, भारत सरकार
WHO Collaborating Centre For Research and Training On Diarrhoeal Diseases

NICED : Scientists

Dr. Moumita Bhaumik Ghosh

Dr. Moumita Bhaumik (Ghosh)

 

General Information
Name Dr. Moumita Bhaumik (Ghosh)
Designation Scientist D
Date of joining ICMR 06 November 2017
Date of joining present post 06 November 2017
Discipline Immunology
Division  
Specialization  
Email : drmoumitabhaumik@gmail.com
Academic Qualification  
Graduation Zoology, University of Calcutta
Post Graduation Biophysics and Molecular biology. University of Calcutta
Doctoral Biophysics and Molecular biology, CSIR-IICB, Kolkata

Profile

Research Experience

My doctoral research experience revolved around the pathogenesis of the Leishmania infection. Leishmania, a protozoan parasite causing the disease Kala-azar exhibit a pronounced tropism for macrophages. Once, the parasite is well established, it causes aberrant changes in macrophage property and function. My study was designed to understand the 'complex rules' by which Leishmania parasites modulate the biological functions of the macrophage affecting the antileishmanial immune repertoire. All the studies were restricted on three aspects of cell biology of Leishmania infected macrophage - the macrophage membrane function, effective immune stimulation by antileishmanial drugs and antigen processing and presentation of exogenous antigen. Thus, it was shown how Leishmania parasites modulate the macrophage function which may have significant impact on the immunopathology of Leishmaniasis.
 

Research Interest

  1.  To study the effect of prenatal arsenic exposure on postnatal life specially focusing on the immune parameters, gut microbiome and gut physiology.
  2.  Gut microbiome and its associated metabolites have been shown to involve in obesity, immunological disorders, enteric infections, colitis and many more. We elucidate the molecular details of various physiological regulations by the metabolites.
  3.  With the emergence of Covid19 pandemic, we thrust our interest to develop various strategies to increase immunogenicity of the available Covid 19 vaccines either by heterologous prime boost immunization or using BCG as an adjuvant.
     

Awards

  1. A. K. Memorial medal for first class first in B.Sc(Zoology) from University of Calcutta (2004)

Miscellaneous:

Projects:
Extramural (Title, Duration)
  1. "Assessment of prophylactic and therapeutic role of BCG against SARS CoV2 infection: study in hamster model" DBT-BIRAC , 2021-2022
  2.  "Sphingolipid as mediator in the interface of microbiome and host: implication in gut pathology" DST-SERB, 2021-2024.
  3.  "Comparative assessment of immune responses following covaxin, covishield, sputnik-V and development of a novel vaccine candidate using doggybone/ (MIDGE) DNA encoding SARSCoV2-spike protein for employing alongside current vaccines in heterologous prime-boost approach in mice" ICMR, 2022-2025.

Intramural (Title, Duration)

"The role of short chain fatty acid in cholesterol homeostasis: implication in gut immunology" 2018-2022

Students (Please include names of students presently working in the lab)

Mainak Chakraborty (CSIR-SRF)
Oishika Das (DST-SRF)
Ankita Dutta (Project SRF)
Aaheli Masid (CSIR-JRF)
 Travel to foreign countries to attend conference/ meetings (for the last 5 years):
 

Publications

2023

  1. Das O, Masid A, Chakraborty M, Gope A, Dutta S, Bhaumik M*.Butyrate driven raft disruption trots off enteric pathogen invasion: possiblemechanism of colonization resistance. GutPathog. Apr 21 2023;15(1):19. doi:10.1186/s13099-023-00545-0.
  2. Chakraborty M, Gautam A, Das O, Masid A, Bhaumik M*.Prenatal arsenic exposure stymies gut butyrate production and enhances gutpermeability in post natal life even in absence of arsenic deftly throughmiR122-Occludin pathway. Toxicol Lett.Feb 1 2023;374:19-30. doi:10.1016/j.toxlet.2022.11.011.

2022

  1. Das O, Kundu J, Ghosh A, Gautam A, Ghosh S, Chakraborty M,Masid A, Gauri S S, Mitra D, Dutta M, Mukherjee B, Sinha S, Bhaumik M*.AUF-1 knockdown in mice undermines gut microbial butyrate-drivenhypocholesterolemia through AUF-1-Dicer-1-mir-122 hierarchy. Front Cell Infect Microbiol.2022;12:1011386. doi:10.3389/fcimb.2022.1011386.
  2. Alcantara LCJ, Amenga-Etego L, Andersson R, Bhaumik https://pubmed.ncbi.nlm.nih.gov/35396474/ - affiliation-4 M, Choi YK, Helene Decaluwe H Geoghegan J, Haagmans BL, Lopez S, Mukhtar MM, Nelwan E, Rahal EA, Sato K, Sklan EH, Fang YSC. Methods for fighting emerging pathogens. Nat Methods (Focus Feature).2022, 19(4):395-397.

2020

  1. Chakraborty M and Bhaumik M. Prenatal Arsenic Exposure Interferes in Postnatal Immunocompetence despite an Absence of Ongoing Arsenic Exposure. J. Immunotoxicology. 2020, 17(1):135

 

2014

  1. Ghosh M, Roy K, Das Mukherjee D, Chakrabarti G, Roy Choudhury K, Roy S. Leishmania donovani infection enhances lateral mobility of macrophage membrane protein which is reversed by liposomal cholesterol. PLoS Negl Trop Dis. 2014 Dec 4;8(12):e3367. .  Pubmed
  2. Roy K, Naskar K, Ghosh M, Roy S. Class II MHC/peptide interaction in Leishmania donovani infection: implications in vaccine design. J Immunol. 2014 Jun 15;192(12):5873-80 Pubmed

2013

  1. Ghosh M, Roy K, Roy S. Immunomodulatory effects of antileishmanial drugs. J Antimicrob Chemother. 2013 Dec;68(12):2834-8  Pubmed
  2. Roy K, Ghosh M, Pal TK, Chakrabarti S, Roy S. Cholesterol lowering drug may influence cellular immune response by altering MHC II function. J Lipid Res. 2013 Nov;54(11):3106-15.   Pubmed
  3. Ghosh M, Solanki AK, Roy K, Dhoke RR, Ashish, Roy S. Carrier protein influences immunodominance of a known epitope: implication in peptide vaccine design. Vaccine. 2013 Sep 23;31(41):4682-8.   Pubmed

2012

  1. Datta S, Manna M, Khanra S, Ghosh M, Bhar R, Chakraborty A, et al. Therapeutic immunization with radio-attenuated Leishmania parasites through i.m. route revealed protection against the experimental murine visceral leishmaniasis. Parasitology research. 2012;111(1):361-9.  Pubmed

2011

  1. Bhattacharya P, Gupta G, Majumder S, Adhikari A, Banerjee S, Halder K, et al. Arabinosylated lipoarabinomannan skews Th2 phenotype towards Th1 during Leishmania infection by chromatin modification: involvement of MAPK signaling. PloS one. 2011;6(9):e24141. Pubmed

2009

  1. Banerjee S, Ghosh J, Sen S, Guha R, Dhar R, Ghosh M, et al. Designing therapies against experimental visceral leishmaniasis by modulating the membrane fluidity of antigen-presenting cells. Infection and immunity. 2009;77(6):2330-42. Pubmed